106 related articles for article (PubMed ID: 8337733)
1. Antileishmanial activity of the ether phospholipid ilmofosine.
Croft SL; Neal RA; Thornton EA; Herrmann DB
Trans R Soc Trop Med Hyg; 1993; 87(2):217-9. PubMed ID: 8337733
[TBL] [Abstract][Full Text] [Related]
2. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.
Croft SL; Snowdon D; Yardley V
J Antimicrob Chemother; 1996 Dec; 38(6):1041-7. PubMed ID: 9023651
[TBL] [Abstract][Full Text] [Related]
3. The activity of platinum, iridium and rhodium drug complexes against Leishmania donovani.
Croft SL; Neal RA; Craciunescu DG; Certad-Fombona G
Trop Med Parasitol; 1992 Mar; 43(1):24-8. PubMed ID: 1598504
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
[TBL] [Abstract][Full Text] [Related]
5. Effect of allicin on promastigotes and intracellular amastigotes of Leishmania donovani and L. infantum.
Jesús Corral-Caridad M; Moreno I; Toraño A; Domínguez M; Alunda JM
Exp Parasitol; 2012 Dec; 132(4):475-82. PubMed ID: 22995646
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani.
Nakayama H; Desrivot J; Bories C; Franck X; Figadère B; Hocquemiller R; Fournet A; Loiseau PM
Biomed Pharmacother; 2007; 61(2-3):186-8. PubMed ID: 17360145
[TBL] [Abstract][Full Text] [Related]
7. Aspects of the cytological activity of edelfosine, miltefosine, and ilmofosine in Leishmania donovani.
Azzouz S; Maache M; Dos Santos MF; Sarciron ME; Petavy AF; Osuna A
J Parasitol; 2006 Oct; 92(5):877-83. PubMed ID: 17152926
[TBL] [Abstract][Full Text] [Related]
8. Leishmanicidal activity of edelfosine, miltefosine and ilmofosine.
Azzouz S; Maache M; Garcia RG; Osuna A
Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):60-5. PubMed ID: 15667597
[TBL] [Abstract][Full Text] [Related]
9. Potential of doxorubicin as an antileishmanial agent.
Sett R; Basu N; Ghosh AK; Das PK
J Parasitol; 1992 Apr; 78(2):350-4. PubMed ID: 1556650
[TBL] [Abstract][Full Text] [Related]
10. Suppression of both antimony-susceptible and antimony-resistant Leishmania donovani by a bis(benzyl)polyamine analog.
Baumann RJ; Hanson WL; McCann PP; Sjoerdsma A; Bitonti AJ
Antimicrob Agents Chemother; 1990 May; 34(5):722-7. PubMed ID: 2360812
[TBL] [Abstract][Full Text] [Related]
11. Effect of sodium stibogluconate and pentamidine on in vitro multiplication of Leishmania donovani in peritoneal macrophages from infected and drug-treated BALB/c mice.
Sodhi S; Kaur S; Mahajan RC; Ganguly NK; Malla N
Immunol Cell Biol; 1992 Feb; 70 ( Pt 1)():25-31. PubMed ID: 1322361
[TBL] [Abstract][Full Text] [Related]
12. 3'-Deoxy-3'-fluoroinosine as a potent antileishmanial agent. The metabolism and selective cytotoxic effect of 3'-deoxy-3'-fluoroinosine against Leishmania tropica and L. donovani in vitro and in vivo.
Shin IS; Tanifuji H; Arata Y; Morizawa Y; Nakayama T; Wataya Y
Parasitol Res; 1995; 81(7):622-6. PubMed ID: 7479655
[TBL] [Abstract][Full Text] [Related]
13. Eugenol derived immunomodulatory molecules against visceral leishmaniasis.
Charan Raja MR; Velappan AB; Chellappan D; Debnath J; Kar Mahapatra S
Eur J Med Chem; 2017 Oct; 139():503-518. PubMed ID: 28826085
[TBL] [Abstract][Full Text] [Related]
14. The sensitivity of Leishmania species to aminosidine.
Neal RA; Allen S; McCoy N; Olliaro P; Croft SL
J Antimicrob Chemother; 1995 May; 35(5):577-84. PubMed ID: 7592170
[TBL] [Abstract][Full Text] [Related]
15. Asiaticoside induces tumour-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony-susceptible and -resistant Leishmania donovani strains.
Bhaumik SK; Paul J; Naskar K; Karmakar S; De T
J Antimicrob Chemother; 2012 Apr; 67(4):910-20. PubMed ID: 22258930
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antileishmanial activity of some 1- or 2-(dihydroxyalkyl) and 3-(dihydroxyalkoxy)pyrazolo [3,4-d] pyrimidines.
Gatta F; Gradoni L; Lupardini E; Gramiccia M; Orsini S
Farmaco; 1991 Jan; 46(1):75-84. PubMed ID: 2054043
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl β-cyclodextrin formulation and pharmacokinetics via intravenous route.
Balaraman K; Vieira NC; Moussa F; Vacus J; Cojean S; Pomel S; Bories C; Figadère B; Kesavan V; Loiseau PM
Biomed Pharmacother; 2015 Dec; 76():127-33. PubMed ID: 26653559
[TBL] [Abstract][Full Text] [Related]
18. Antileishmanial effects of clofazimine and other antimycobacterial agents.
Evans AT; Croft SL; Peters W; Neal RA
Ann Trop Med Parasitol; 1989 Oct; 83(5):447-54. PubMed ID: 2619361
[TBL] [Abstract][Full Text] [Related]
19. In vivo antileishmanial action of Ir-(COD)-pentamidine tetraphenylborate on Leishmania donovani and Leishmania major mouse models.
Loiseau PM; Mbongo N; Bories C; Boulard Y; Craciunescu DG
Parasite; 2000 Jun; 7(2):103-8. PubMed ID: 10887656
[TBL] [Abstract][Full Text] [Related]
20. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.
Gupta S; Yardley V; Vishwakarma P; Shivahare R; Sharma B; Launay D; Martin D; Puri SK
J Antimicrob Chemother; 2015 Feb; 70(2):518-27. PubMed ID: 25389223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
